Skip to main content
Premium Trial:

Request an Annual Quote

AGY Therapeutics Turns to Cengent for X-Ray Crystallography

NEW YORK, June 30 - Cengent Therapeutics, formed by the merger in May of Structural Bioinformatics and GeneFormatics, said today that it has signed an agreement with AGY Therapeutics for its X-ray crystallography services.


Cengent's technology will be used to produce high-resolution structures of a human target protein and a proprietary inhibitor for AGY's lead optimization efforts in the area of central nervous system disease.


The agreement includes up-front and milestone payments, Cengent said. The company did not provide further financial details.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.